title: Effect of precalving intramammary treatment with pirlimycin in nulliparous Holstein heifers.
abstract: A clinical trial was conducted to determine whether prepartum intramammary pirlimycin reduces the proportion of nulliparous heifers with intramammary infection (IMI) during early lactation and improves milk production. Quarter milk samples were collected from 428 heifers, systematically allocated to treatment and control groups, 6 to 12 d before the expected calving date and 2 to 8 d after calving. At the prepartum visit, heifers in the treatment group (n = 219) received an infusion of pirlimycin hydrochloride in all 4 quarters; the control heifers (n = 209) received no infusions. Intramammary infection was detected in 69% of the heifers and 33% of the quarters before calving. After calving, the proportion of treated heifers with IMI was significantly lower than the proportion of control heifers (31% versus 45%). Staphylococcus aureus was isolated from 10% of the heifers and 3% of the quarters before calving. After calving, the proportion of IMIs due to S. aureus was significantly lower in the treated heifers than in the control heifers (5.6% versus 10%). Antibiotic treatment increased the percentage of cures and prevented new IMIs caused by gram-positive bacteria after calving. The incidence of new IMIs caused by gram-negative bacteria and yeast was higher among treated heifers than among control heifers. There was no overall effect of treatment on milk production, but there was a significant interaction effect of treatment and the interval between treatment and calving. An increase of 302 kg of milk was observed when antibiotic treatment was applied more than 1 wk before calving. Treatment did not affect the milk somatic cell count on the 1st 3 test days after calving.
authors.affiliation: Département de sciences cliniques, Faculté de médecine vétérinaire, Université de Montréal, 3200 rue Sicotte, Saint-Hyacinthe, Quebec J2S 2M2. jean-philippe.roy@umontreal.ca
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Roy
authors.forename: Denis
authors.initials: D
authors.lastname: Du Tremblay
authors.forename: Luc
authors.initials: L
authors.lastname: DesCôteaux
authors.forename: Serge
authors.initials: S
authors.lastname: Messier
authors.forename: Daniel
authors.initials: D
authors.lastname: Scholl
authors.forename: Emile
authors.initials: E
authors.lastname: Bouchard
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002417:Cattle; D002452:Cell Count / Q000662:veterinary; D002981:Clindamycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D008414:Mastitis, Bovine / Q000453:epidemiology / Q000517:prevention & control*; D008892:Milk / Q000737:chemistry / Q000166:cytology / Q000382:microbiology; D010298:Parity; D011247:Pregnancy; D011446:Prospective Studies; D011897:Random Allocation; D013203:Staphylococcal Infections / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary*; D013211:Staphylococcus aureus / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D002981:Clindamycin; C034093:pirlimycin